RT期刊文章SR电子T1改良Rankin秤在第四天卒中后残疾状态是90年最后一天的信息预测结果(P6.271)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P6.271 VO 88是16补充A1塞缪尔Asanad A1西德尼·斯达克曼A1斯科特·汉密尔顿A1罗宾Conwit A首页1合作伙伴Sanossian A1 Jeffrey节省年2017 UL //www.ez-admanager.com/content/88/16_Supplement/P6.271.abstract AB目的:描绘一个早期的预测价值,4 d改良Rankin规模(夫人)在预测最后的90 d夫人的结果。背景:最终的卒中后残疾标准评估3个月post-onset,使用改良Rankin规模。可靠的方法推导出基于最初的90 d夫人医院课程需要项目结果失访的患者出院后在关键的临床试验和临床质量改进项目。设计/方法:我们确定了所有急性脑缺血和颅内出血患者与4 d和90 d夫人在NIH领域评估政府的中风治疗——镁(FAST-MAG) 3期临床试验。4 d RS单独的性能预测90 d夫人是评估使用相关系数和加权kappa协议。多变量预测模型的90 d夫人一分为二的结果是4 d夫人和16个候选基线变量。试验结果:招收了1633名急性脑血管疾病患者记录分数夫人这两天4到90年,其中1245(76.2%)与急性脑缺血和387年(23.7%)急性颅内出血。在这些病人中,4 d和90 d夫人夫人紧密相关,r = 0.79。加权kappa协议4 d、90 d夫人是温和的,为0.59。一分为二的结果,简单的结转的4 d夫人一天90表现相当好,同意90 d夫人速度:0 - 1夫人,85%;夫人0 - 2,79%;致命的结果,88%。 Multivariate models additionally incorporating baseline variables improved agreement rates to: mRS 0–1, 93%; mRS 0–2, 85%; fatal outcome, 97%.Conclusions: In acute stroke patients, the 4d modified Rankin global disability assessment is highly informative regarding final 3 month mRS disability outcome, alone, and even more strongly in combination with baseline prognostic variables. The 4d mRS is a useful measure for imputing final patient disability outcome in clinical trials and quality improvement programs.Disclosure: Dr. Asanad has nothing to disclose. Dr. Starkman has received research support from the National Institute of Health, Stryker, Biogen IDEC, Neuravi, Genentech, Covidien, and Astra-Zeneca. Dr. Hamilton has nothing to disclose. Dr. Conwit has nothing to disclose. Dr. Sanossian has recieved personal compensation for activities with Covidien Inc., serving on the clinical events committee and from Genentech as a speak.. Dr. Saver has received personal compensation for activities with Medtronic, Stryker, Neuravi, and Boehringer Ingelheim as a consultant. Dr. Saver has received personal compensation in an editorial capacity for JAMA. Dr. Saver has received research support from Medtronic and Stryker.